Transcript Solid Tumors

Solid Tumors
Anthony W. Stephens, M.D.
2015
1
Cancer





Characteristics
– abnormal cell growth
– spread/metastasis
Incidence (U.S)
– 1.6 million/year
– 600,000 deaths (1500 / day)
– 77% of all cancers in age >55
Survival approximately 67% at 5 years
– Was 49% in the 1970’s
2nd leading cause of death in the US
Accounts for 1 of every 4 deaths
2
Breast Cancer

Most common cancer in U.S. women

Second leading cause of cancer deaths

1 out of 8 women affected in their lifetime

can also affect men (1%)

Slight decrease in incidence from 19992006 by 2%/year
3
Breast Cancer

Scope
– 232,000 cases/year
– 40,000 deaths/year

Incidence highest in North America and
Europe, lowest in Asia and Africa

Mortality declining by 2.5% since 1990’s

2.9 million survivors living in U.S. today
4
Breast Ca: Etiology

Risk factors:
–
–
–
–
–
–
–
–
–
–
family history/genetics
Increasing age/gender
hormonal factors
diet/lifestyle (obesity/inactivity)
Weight gain after age 18
Radiation exposure
alcohol intake (>1/day)
high breast density
High bone mineral density
LCIS in either breast
5
Breast Ca: Etiology

Hormonal Factors
–
–
–
–
–

Early menarche
Late menopause
Nulliparity
1st pregnancy> 30 years
Menopausal hormone therapy (MHT)
Protective Factors
–
–
–
–
–
Breastfeeding
Avoid weight gain
Limit alcohol
Exercise
Tamoxifen / Raloxifene
6
Types of Breast Cancer

Ductal

Lobular

In situ vs. Invasive

Less common (mucinous, tubular,
metaplastic)

Inflammatory (1-2%)


Very aggressive, red/swollen/inflamed
Paget’s disease
7
Breast Cancer: Genetics

Positive family history in 15-20% of
patients (most patients do not have a
family history)

Do not neglect paternal family history

RR:
– one 1st degree = 1.8
– two 1st degree = 3

Only 5-10% of breast cancer are due to
specific mutation (e.g. BRCA 1 or 2)
8
Breast Ca: Etiology


Genetics: BRCA 1 mutation
– Accounts for 5% of breast CA
– chromosome 17 short arm
– characteristics:
 early age, bilateral disease
 autosomal dominant
 cumulative risk
 ovarian cancer
 high penetrance
BRCA 2 mutation


Autosomal dominant
Men may be carriers
9
BRCA Testing

Criteria
Counseling
 Psychosocial effects


Interventions / Prophylactic Surgery
(mastectomy, oophorectomy, drugs,
more aggressive screening)
10
Breast Ca: Presentation

Usually asymptomatic (mammogram)

Palpable, painless lump- most benign

Thickening, dimpling, erythema, nipple
retraction or discharge, bleeding, or
persistent pain

Role of mammogram, u/s, biopsy, MRI

Only 5% present with metastases
11
Breast Ca: Screening
Mammography
Reduce mortality by > than 25%
 ACS recommendations: yearly
beginning at age 40
 US Preventive Services Task Force
recommendations (controversial)
 Increase discovery of early stage ca
 False negative rate of 10-15%
 Does not substitute for biopsy
 Risk of false positive result

12
Breast Ca: Screening
Monthly self breast exam
 Annual physician exam
 Role of genetic testing
 Ultrasound – breast density
 MRI

– High risk women (e.g. BRCA)
– In addition to mammography
– Expensive, higher false positive rate
13
Breast Ca: Treatment

Surgery - lumpectomy vs. mastectomy

Sentinel node biopsy

Adjuvant chemotherapy/radiation

Hormonal therapy: Tamoxifen, Aromatase
inhibitors (e.g. Arimidex, Femara)

Targeted Therapies (Herceptin, Tykerb,
Perjeta)
14
Breast Ca: Prognosis

Five year survival: 84-98% for
localized/regional disease

Five year survival: 24% for metastatic disease

Factors: size, lymph node involvement, grade,
hormone receptors, Her2Neu, molecular /gene
expression

Risk of late relapse
15
Lung Cancer: Facts
Incidence:
 Second most common in both sexes
 Leading cause of cancer deaths in males
and females
 226,000/ year diagnosed in US
 160,000 deaths/year in US
 Declining incidence in males > females
16
Lung Cancer: Facts

Survival
– 43% at 1 year
– 16% at 5 years

Accounts for 14% of cancer diagnoses,
28% of cancer deaths

Small advances in recent years
17
Lung Ca: Etiology

Tobacco use causes 80% of cases

Risk increases with pack years

Occupational / Second hand exposure

Associated Ca’s: larynx, oral cavity, pharynx,
esophagus, bladder, cervix, pancreas

Other RF’s: age, asbestos, radon

RR 20-30 in smokers

Some genetic susceptibility
18
Lung Cancer: Type

Adenocarcinoma = 35-45%

Squamous Cell = 20-30%

Large Cell = 10%

Small Cell = 15%
19
Lung Ca: Presentation

Few “early” symptoms

Persistent cough, pneumonia, hoarseness, hemoptysis,
dyspnea, chest pain, bone pain, weight loss

Abnormal chest x-ray (10% of patients)

Paraneoplastic Syndromes (e.g. Ca++, SIADH, clubbing)
20
Lung Ca: Screening

Chest x-ray, sputum cytology
– No benefit

Chest CT , sputum molecular markers
– Low dose, spiral CT reduced mortality by 20%
in heavy smokers
21
Lung Ca: Diagnosis

Abnormal chest x-ray

Chest/abdomen CT scan

Bronchoscopy/ biopsy

Staging (e.g.: head CT, bone scan)

PET scan
22
Lung Ca: Treatment

Defined by type and stage

Surgical resection, if feasible

Radiation/chemotherapy

Survival
– Dependent on Stage, health of patient

Targeted therapy (e.g. Tarceva, Avastin, Xalkori)
23
Lung Ca: Treatment
DON’T SMOKE!
24
Prostate Ca: Facts

Most common cancer in U.S. males (240,000/year)

One of six US males

Incidence higher in African Americans

Mortality rates have been declining since 1990’s

Second leading cause of cancer death in men
(29,000/year)
25
Prostate Ca: Risk Factors

Associated with advanced age

> 80% diagnosed beyond age 65

Highest incidence in African-Americans
– Younger age at diagnosis

Family history / genetics (5-10% cases)

High saturated fat diet
26
Prostate Ca: Presentation

Many are asymptomatic (PSA Screen)

Difficulty with urination, hematuria,
nocturia, dysuria

Bone pain from metastasis
27
Prostate Ca: Evaluation

Digital rectal exam (DRE)

Trans-rectal ultrasound, biopsy

PSA, alk phos

Pelvic CT, bone scan

Abdomen/pelvis CT, Bone scan
28
Prostate Ca: Treatment

Dependent upon stage, age, medical condition

Options include surgery and radiation for
localized disease, Immunotherapy,
Radiopharmaceutical

Hormonal therapy, chemotherapy for advanced
disease

“Active Surveillance” or “Watchful Waiting”
appropriate for low grade tumors and for older
men
29
Prostate Ca: Survival

Dependent upon stage at diagnosis, grade
of tumor, medical condition

Metastasis usually involves bones

Survival can be very long

5 year (99%), 15 years (93%)
30
Prostate Ca: Screening

Controversial / ? Survival benefit

US Preventive Services Task Force
– Insufficient data to recommend for or against PSA screening
– Screening trials have yielded conflicting results

ACS recommends
– annual DRE for age > 40
– annual PSA for age > 50
– if either suspicious, then U/S + biopsy
31